CG Oncology, Inc. (NASDAQ:CGON) Director Sells $56,000.00 in Stock

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Leonard E. Post sold 2,000 shares of the stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $28.00, for a total value of $56,000.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Leonard E. Post also recently made the following trade(s):

• On Monday, April 28th, Leonard E. Post sold 1,000 shares of CG Oncology stock. The shares were sold at an average price of $30.76, for a total transaction of $30,760.00.

CG Oncology Stock Down 3.3%

Shares of NASDAQ:CGON traded down $0.89 on Tuesday, hitting $26.01. 1,949,475 shares of the company's stock were exchanged, compared to its average volume of 877,939. The business's 50 day simple moving average is $26.10 and its two-hundred day simple moving average is $26.01. CG Oncology, Inc. has a 12 month low of $14.80 and a 12 month high of $40.47.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.09). The firm had revenue of $0.05 million during the quarter, compared to analysts' expectations of $0.53 million. CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 16.71%. Analysts anticipate that CG Oncology, Inc. will post -1.31 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on CGON shares. The Goldman Sachs Group raised CG Oncology to a "strong-buy" rating and set a $40.00 price target for the company in a research note on Thursday, July 10th. Scotiabank started coverage on CG Oncology in a report on Wednesday, April 16th. They set a "sector perform" rating and a $23.00 target price on the stock. Morgan Stanley increased their target price on CG Oncology from $52.00 to $56.00 and gave the stock an "overweight" rating in a research report on Tuesday, June 17th. Royal Bank Of Canada reduced their price target on CG Oncology from $68.00 to $53.00 and set an "outperform" rating on the stock in a research note on Wednesday, July 16th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $75.00 price objective on shares of CG Oncology in a research report on Monday, April 28th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $55.30.

Hedge Funds Weigh In On CG Oncology

A number of large investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in CG Oncology during the 4th quarter worth about $41,000. CWM LLC raised its holdings in shares of CG Oncology by 3,957.7% in the 1st quarter. CWM LLC now owns 2,110 shares of the company's stock valued at $52,000 after buying an additional 2,058 shares during the period. GAMMA Investing LLC grew its stake in CG Oncology by 1,051.0% during the 1st quarter. GAMMA Investing LLC now owns 2,302 shares of the company's stock worth $56,000 after purchasing an additional 2,102 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in CG Oncology by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company's stock worth $77,000 after acquiring an additional 398 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of CG Oncology during the 4th quarter worth about $100,000. 26.56% of the stock is owned by institutional investors and hedge funds.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.